Drugmaker Glenmark Pharmaceuticals Ltd on Tuesday (December 16) said its wholly owned subsidiary Glenmark Specialty S.A. (GSSA) has entered into an exclusive license, collaboration and distribution agreement with Jiangsu Hansoh Pharmaceutical Group Co, Ltd. for Aumolertinib, a third-generation epidermal growth factor receptor tyrosine kinase inhibitor for the treatment of non-small cell lung cancer.Under the agreement, Glenmark has received exclusive rights to develop and commercialise Aumolertinib across its licensed territories, which include the Middle East and Africa, Southeast and South Asia, Australia, New Zealand, Russia/CIS, and a few selected Caribbean countries covered by the agreement.
As part of the transaction, Hansoh Pharma will receive an upfront payment of low double-digit million USD. The agreement also provides for potential regulatory and commercial milestone payments that may cumulatively exceed $1 billion, along with tiered royalties on net sales in the licensed territories.
Also Read: Glenmark to launch Leucovorin Calcium injection in December 2025 for cancer drug toxicity
“Aumolertinib is a strategic addition that strengthens our near-term commercial pipeline and enhances our ability to serve patients with EGFR-mutated lung cancer. This collaboration reinforces our disciplined approach to expanding our innovative portfolio and widening access to advanced cancer care across key markets,” said Glenn Saldanha, Chairman and Managing Director, Glenmark Pharmaceuticals Ltd.Aumolertinib (marketed as Ameile in China and Aumseqa in the United Kingdom and Europe), as a monotherapy, has received marketing authorisation from the UK MHRA and is indicated for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations, and the treatment of adult patients with locally advanced or metastatic EGFR T790M mutation-positive NSCLC.
As part of the transaction, Hansoh Pharma will receive an upfront payment of low double-digit million USD. The agreement also provides for potential regulatory and commercial milestone payments that may cumulatively exceed $1 billion, along with tiered royalties on net sales in the licensed territories.
Also Read: Glenmark to launch Leucovorin Calcium injection in December 2025 for cancer drug toxicity
“Aumolertinib is a strategic addition that strengthens our near-term commercial pipeline and enhances our ability to serve patients with EGFR-mutated lung cancer. This collaboration reinforces our disciplined approach to expanding our innovative portfolio and widening access to advanced cancer care across key markets,” said Glenn Saldanha, Chairman and Managing Director, Glenmark Pharmaceuticals Ltd.Aumolertinib (marketed as Ameile in China and Aumseqa in the United Kingdom and Europe), as a monotherapy, has received marketing authorisation from the UK MHRA and is indicated for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations, and the treatment of adult patients with locally advanced or metastatic EGFR T790M mutation-positive NSCLC.
It has also received approval for four indications in China (second-line T790M mutation, first-line NSCLC EGFR mutated, unresectable Stage III post-chemoradiotherapy, and adjuvant Stage II–IIIB NSCLC). Aumolertinib became Hansoh Pharma’s first innovative drug approved in an overseas market and the first China-developed EGFR-TKI to be launched internationally.
Shares of Glenmark Pharmaceuticals Ltd ended at ₹1,962.00, down by ₹23.60, or 1.19%, on the BSE.
Also Read: Glenmark Pharma US arm to launch injection to control excess acid production in body
